根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号 ——回购股份》等相关规定，现将公司第五届董事会第五次会议决议公告的前一个 交易日（即 2025 年 12 月 30 日）登记在册的前十名股东和前十名无限售条件股东的 名称、持股数量和比例情况公告如下： | 序号 | 股东名称 | 总持有数量 | 占总股本比 | | --- | --- | --- | --- | | | | （股） | 例（%） | | 1 | 朱义 | 298,159,400 | 72.22 | | 2 | OAP III (HK) Limited | 28,527,171 | 6.91 | | 3 | 张苏娅 | 9,575,543 | 2.32 | | 4 | 中国工商银行股份有限公司－中欧医 疗健康混合型证券投资基金 | 5,426,546 | 1.31 | | 5 | 招商银行股份有限公司－华夏上证科 创板 50 成份交易型开放式指数证券投 | 3,185,228 | 0.77 | | | 资基金 | | | | 6 | 中国工商银行股份有限公司－易方达 上证科创板 50 成份交易型开放式指数 | 3,031 ...

百利天恒公告称，拟以集中竞价交易方式回购股份，金额不低于10000万元、不超过20000万元，价格不 超过546元/股。回购期限自董事会审议通过方案起12个月内。回购股份将用于员工持股计划或股权激 励，若3年内未使用完毕，未使用部分将注销。截至2025年9月30日，按回购资金上限测算，占总资产、 净资产等比例有限，不会对公司产生重大影响。目前，董监高、控股股东等未来3、6个月暂无减持计 划。但本次回购存在价格、重大事项等风险。 ...

Group 1 - The core message of the news is that China's National Medical Products Administration (NMPA) will enhance support for innovative drugs with new mechanisms and targets throughout the entire process from communication, clinical trials, registration, to review and approval, promoting "China's first launch" of innovative drugs [1][5] - By 2025, it is projected that 76 innovative drugs will be approved for market in China, with 80.85% of chemical drugs being domestic innovations and 91.3% of biological products being domestically developed [5][6] - The internationalization of China's pharmaceutical industry is advancing, with cumulative overseas licensing transactions for innovative drugs exceeding $130 billion, marking a shift from a "generic drug manufacturing powerhouse" to an "innovative drug exporting powerhouse" [6] Group 2 - The A-share market is seeing a strong performance in innovative drug concept stocks, with companies like Beibite-U and Hongbo Pharmaceutical experiencing significant price increases [2][3] - As of the end of 2025, the total market capitalization of 158 innovative drug concept stocks in the A-share market reached 3.42 trillion yuan, with several companies achieving over 100 billion yuan in market value [12][14] - The innovative drug sector is expected to remain a key investment theme in 2026, with a focus on clinical progress and data validation for pipelines that have already entered overseas markets [12][16]

Core Viewpoint - The Hong Kong stock market for innovative drugs has experienced a rally since the beginning of 2026, driven by positive clinical data from Arrowhead, which has boosted sentiment in the sector [1]. Group 1: Market Performance - The Hong Kong Stock Connect Innovative Drug ETF (159570) has shown strong performance, with a nearly 2% increase and a trading volume exceeding 9 billion, indicating high trading activity [6]. - As of January 7, 2026, the ETF's latest scale has surpassed 24.7 billion, leading its peers in the same category [6]. - The majority of the weighted stocks in the ETF index have shown positive performance, with notable increases from companies like Sanofi and Innovent Biologics [2]. Group 2: Company News - Strong Brain Technology, a brain-computer interface "unicorn," has completed a financing round of 2 billion, second only to Musk's Neuralink [1]. - Insilico Medicine, an AI-driven pharmaceutical company, has announced a long-term collaboration with Sihuan Pharmaceutical for anti-tumor drug development, with a total cooperation amount of 888 million [1]. Group 3: Industry Trends - The innovative drug industry is expected to continue its upward trend, with catalysts on the horizon. The market anticipates a busy period for business development (BD) transactions and data disclosures in early 2026 [4]. - The upcoming J.P. Morgan Healthcare Conference is expected to attract over 8,000 global participants, showcasing advancements in biotechnology, pharmaceuticals, and medical devices [5]. - Three major trends are emerging in the industry: the continued rise of gene and cell therapies, deep integration of AI in pharmaceuticals, and the rise of emerging market players [7]. Group 4: Investment Insights - The average total package for top multinational corporations (MNCs) purchasing innovative drugs or technology platforms from China in 2025 is 2.756 billion, indicating a willingness to pay higher prices for Chinese innovations [8]. - The focus of MNCs is shifting from merely acquiring products to obtaining platforms and time, emphasizing the importance of technology platforms that can produce new molecules [10]. - Investment logic suggests that MNCs are willing to pay premiums for clinically validated assets, particularly those that can fill pipeline gaps and provide immediate revenue [11].

Group 1 - The overall market sentiment for innovative drug overseas BD transactions has shifted from extreme optimism to a more rational understanding, leading to significant stock price declines for many small companies in the A-share and H-share markets [1] - The driving logic for the innovative drug industry in 2026 will rely on tangible overseas clinical advancements and increased certainty in overseas commercialization, moving away from transient BD transactions [1] - Major companies in the innovative drug sector, including industry leaders and quality second-tier companies, are beginning to stabilize and show upward trends in stock prices [1] Group 2 - Two significant oncology drugs, AK112 from Kangfang Biotech and SKB264 from Kelun-Biotech, are expected to have major impacts in their respective fields, with ongoing clinical trials and potential breakthroughs [3] - Kangfang Biotech's AK112 has seen a series of clinical advancements that have sparked global interest in second-generation IO development, leading to multiple impactful BD transactions [3] - SKB264 is positioned as a potential global first-in-class drug in the ADC category, with ongoing clinical trials and a significant focus on its efficacy in various cancers [5] Group 3 - Kangfang Biotech is expected to read out three major Phase III clinical results in 2026, including two first-line lung cancer trials, with potential approval timelines set for 2025 and 2027 [4] - Kelun-Biotech's SKB264 is anticipated to read out important clinical results for two major indications in 2026, which could validate its market potential outside of China [7] - The innovative drug industry is expected to see significant clinical progress from various companies that have engaged in substantial BD transactions in 2024-2025, enhancing the long-term value of their overseas projects [7][9]

登录新浪财经APP 搜索【信披】查看更多考评等级 一、股份回购方案基本情况 四川百利天恒药业股份有限公司（以下简称"公司"）于2025年12月30日召开了第五届董事会第五次会 议，审议通过了《关于以集中竞价交易方式回购公司股份方案的议案》，同意公司使用自有资金和/或 自筹资金以集中竞价交易方式回购公司已发行的部分人民币普通股（A股）股票，拟回购资金总额不低 于人民币10,000万元（含），不超过人民币20,000万元（含），回购的股份将在未来适宜时机全部用于 实施员工持股计划或股权激励。本次回购价格不超过人民币546元/股（含），回购股份期限为自公司董 事会审议通过股份回购方案之日起12个月内。 具体内容详见公司于2025年12月31日刊登于上海证券交易所网站（www.sse.com.cn）的《四川百利天恒 药业股份有限公司关于以集中竞价交易方式回购股份的预案》（公告编号：2025-093）。 二、取得金融机构股票回购专项贷款承诺函的具体情况 近日，公司取得中国银行股份有限公司四川省分行出具的《贷款承诺函》，主要内容如下： 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688506 证券简称：百利天恒 公告编号：2026-002 四川百利天恒药业股份有限公司 关于取得金融机构股票回购专项贷款承诺函的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 一、股份回购方案基本情况 四川百利天恒药业股份有限公司（以下简称"公司"）于2025年12月30日召开了第五届董事会第五次会 议，审议通过了《关于以集中竞价交易方式回购公司股份方案的议案》，同意公司使用自有资金和/或 自筹资金以集中竞价交易方式回购公司已发行的部分人民币普通股（A股）股票，拟回购资金总额不低 于人民币10,000万元（含），不超过人民币20,000万元（含），回购的股份将在未来适宜时机全部用于 实施员工持股计划或股权激励。本次回购价格不超过人民币546元/股（含），回购股份期限为自公司董 事会审议通过股份回购方案之日起12个月内。 具体内容详见公司于2025年12月31日刊登于上海证券交易所网站（www.sse.com.cn）的《四川百利天恒 药业股份有限公司关于以 ...

（编辑 任世碧） 证券日报网讯 1月7日，百利天恒发布公告称，近日，公司取得中国银行股份有限公司四川省分行出具 的《贷款承诺函》，主要内容如下：1、贷款承诺额度：不超过1.8亿元人民币。2、贷款期限：3年。 3、贷款用途：专项用于回购公司股份。 ...

Core Viewpoint - Sichuan Baili Tianheng Pharmaceutical Co., Ltd. has obtained a loan commitment of up to 180 million RMB from Bank of China Sichuan Branch to support its share repurchase plan [1][3]. Group 1: Share Repurchase Plan - The company approved a share repurchase plan on December 30, 2025, intending to use self-owned and/or self-raised funds to repurchase A-shares through centralized bidding, with a total repurchase amount between 100 million RMB and 200 million RMB, and a maximum repurchase price of 546 RMB per share [2]. - The repurchase period is set for 12 months from the date of the board's approval, with the repurchased shares planned for future employee stock ownership plans or equity incentives [2]. Group 2: Loan Commitment Details - The loan commitment specifies that the funds are to be used exclusively for the repurchase of company shares, with a loan term of three years [3]. - The actual details of the loan will be formalized in a stock repurchase loan contract between the company and the bank [3]. Group 3: Additional Notes - The loan commitment enhances the flexibility of the company's repurchase funds and reflects the financial institution's recognition of the company's growth prospects [4]. - The company clarifies that the loan does not guarantee the total repurchase amount, and the actual number of shares repurchased will depend on market conditions and fund availability [4].

Group 1 - The company, Baili Tianheng (688506.SH), has received a loan commitment letter from the Bank of China Sichuan Branch [1] - The loan commitment amount is up to 180 million RMB [1] - The loan term is set for 3 years, specifically for the purpose of repurchasing the company's shares [1]